Announcements
- Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
- Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
- Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
Key statistics
On Friday, Cosmo Pharmaceuticals NV (C43:MUN) closed at 55.00, 30.33% above the 52 week low of 42.20 set on Jun 20, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 55.00 |
---|---|
High | 55.00 |
Low | 55.00 |
Bid | -- |
Offer | -- |
Previous close | 54.50 |
Average volume | 4.55 |
---|---|
Shares outstanding | 17.54m |
Free float | 9.25m |
P/E (TTM) | 29.62 |
Market cap | 973.67m CHF |
EPS (TTM) | 1.87 CHF |
Annual div (ADY) | 0.95 EUR |
---|---|
Annual div yield (ADY) | 1.73% |
Div ex-date | Jun 01 2022 |
Div pay-date | Jun 03 2022 |
Data delayed at least 15 minutes, as of Mar 24 2023 07:02 BST.
More ▼